
The FY2027 appropriations process gives Congress an immediate opportunity to protect medical cannabis patients from discrimination while addressing the gaps left by the Attorney General's order. Through funding directives, legislative provisions, and committee report language, Congress can require federal agencies to protect patients, update outdated policies, and establish the safeguards necessary for safe access and healthcare integration. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are not left behind while Congress develops a national framework.
For ASA's complete appropriations agenda, detailed requests across all seven subcommittees, and the latest congressional developments, visit our FY2027 Medical Cannabis Appropriations Hub. The hub will be updated as Congress considers FY2027 funding legislation and patient advocacy opportunities.
DOWNLOAD PROPOSED HHS APPROPS LANGUAGE| TAKE ACTION
LABOR, HEALTH & HUMAN SERVICES, EDUCATION & RELATED AGENCIES COMMITTEE ASKS
Cannabis medicines are used to treat a variety of medical conditions in the U.S., with patients consistently reporting improved quality of life, reduced pain, better sleep, enhanced mood, and increased mobility with fewer side effects. These experiences have been validated by a growing body of scientific evidence and by HHS, the FDA, the NIH, and the National Academies of Science. HHS is the natural oversight agency for medical cannabis, and they should find ways to learn more about the experiences of patients and medical professionals are having with cannabis medicines as they wait for Congress to create a framework for nationwide access and healthcare integration strategies.

The Department of Health and Human Services (HHS) has a central role in integrating medical cannabis into American healthcare. Although HHS determined in 2023 that cannabis has a currently accepted medical use in the United States, federal healthcare programs have not established the coordinated policies, clinical data systems, research infrastructure, or oversight necessary to support patients receiving cannabis medicines. As a result, patients may continue to encounter barriers to medical documentation, clinical guidance, care coordination, and reasonable accommodation in federally funded healthcare settings.
Millions of patients participate in state medical cannabis programs to manage chronic pain, sleep disturbances, and other medical conditions, with many reporting improvements in symptoms and quality of life. Scientific research and decades of clinical experience have contributed to federal recognition of cannabis' therapeutic value, but important questions remain about treatment outcomes, dosing, drug interactions, long-term safety, and potential healthcare costs or savings. Federal healthcare agencies need consistent information from patients and healthcare professionals to better understand these therapies and develop appropriate clinical standards.
Congress should direct HHS and the Centers for Medicare & Medicaid Services (CMS) to address existing barriers to patient care, develop standardized medical cannabis data collection, evaluate coverage models and healthcare costs, and establish a coordinated federal approach to medical cannabis oversight. Federal recognition of cannabis' medical value must be followed by policies that support informed clinical decisions, protect patients from discriminatory exclusions, and prepare the healthcare system to integrate cannabis medicines safely and effectively.
ASA'S FY2027 APPROPRIATIONS REQUEST |
Americans for Safe Access requests that Congress direct HHS and CMS to review and update federal healthcare guidance affecting patients participating in state-authorized medical cannabis programs. This guidance should address medical documentation, individualized clinical decisions, care coordination, and applicable disability protections across hospitals, hospices, nursing homes, assisted living facilities, federally qualified health centers, transplant and pain management programs, and Medicare and Medicaid providers.
Congress should also require standardized electronic health record fields for therapeutic medical cannabis, expanded research and real-world evidence collection, and studies evaluating healthcare expenditures, potential cost savings, and appropriate coverage models. These measures would help federal agencies understand patient experiences, assess therapeutic outcomes, identify safety concerns, and develop evidence-based approaches to clinical care.
ASA further requests that Congress establish an Office of Medical Cannabis and Cannabinoid Control within HHS to coordinate federal medical cannabis research, product safety, healthcare data, clinical guidance, and planning for national healthcare integration. This office would provide dedicated federal leadership while Congress develops comprehensive legislation establishing a national medical cannabis regulatory framework.
|
A. HHS & CMS HEALTHCARE GUIDANCE FOR FEDERALLY FUNDED HEALTHCARE ENTITIES |
Direct HHS and CMS to issue guidance requiring federally funded healthcare entities and Medicare- and Medicaid-participating providers to evaluate state-authorized medical cannabis patients through individualized review and reasonable accommodation standards.
Purpose: Patients entering hospitals, hospices, nursing homes, assisted living facilities, FQHCs, transplant programs, pain clinics, and other care settings may be told to discontinue medical cannabis or may be denied documentation, care coordination, or accommodation because providers fear federal funding, certification, reimbursement, or licensing consequences.
PROPOSED BILL LANGUAGE:
SEC. __. MEDICAL CANNABIS PATIENTS IN FEDERALLY FUNDED HEALTHCARE SETTINGS. Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Medicaid Services, shall issue guidance clarifying that federally funded healthcare entities and Medicare- and Medicaid-participating providers may discuss, document, coordinate care for, and reasonably accommodate patients participating in state-authorized medical cannabis programs. Such guidance shall apply to hospitals, hospices, nursing homes, assisted living facilities, federally qualified health centers, transplant programs, pain clinics, Medicare- and Medicaid-participating providers, and other federally funded healthcare entities, and shall require medical cannabis-related requests to be evaluated through individualized assessment, patient safety, clinical judgment, care coordination, and applicable disability nondiscrimination standards.

|
B. STANDARDIZED MEDICAL CANNABIS USE DATA COLLECTION GUIDANCE. |
Direct HHS and CMS to develop standardized intake and electronic health record fields for therapeutic medical cannabis use, separate from non-medical cannabis use, illicit drug use, or substance-use-disorder-related documentation. Standardizing medical cannabis data collection across Medicare, Medicaid, private EMR systems, and NIH research will reduce costly clinical errors, potentially prevent avoidable drug-interaction events, and improve continuity of care. Creating uniform federal data standards also ensures policymakers have reliable, comparable information when evaluating future regulatory or coverage decisions.
Purpose: Standardized documentation will improve patient safety, continuity of care, drug-interaction screening, research comparability, and future policy evaluation.
PROPOSED BILL LANGUAGE:
SEC. __. STANDARDIZED MEDICAL CANNABIS USE DATA COLLECTION & GUIDANCE. The Secretary of Health and Human Services shall use funds made available under this Act to implement standardized data fields and terminology for documenting a patient’s therapeutic cannabis use, including route of administration, chemical composition, dose, and frequency of use, distinct from any questions related to illicit or non-medical cannabis use, within all Medicare (Parts A through D) and Medicaid electronic medical records and patient intake systems. The Secretary shall seek advice from professional organizations such as State medical associations and from clinical experts with demonstrated experience in medical cannabis therapeutics and patient care.
The Secretary shall also develop recommendations and training materials for VHA, private electronic medical record system vendors, and healthcare providers to incorporate comparable data fields to support continuity of care across healthcare settings.
The Secretary shall require that all National Institutes of Health research grants involving cannabis or cannabinoid-related studies utilize the same standardized medical cannabis data set for participant intake and data collection to ensure consistency across federally funded research.
|
C. MEDICAL CANNABIS COST SAVINGS, COVERAGE MODELS, & IMPLEMENTATION COSTS. |
States with medical cannabis programs have reported cost savings to health programs. As Congress is presented with cannabis- and cannabinoid-related policy, it should understand the cost savings for Medicare and Medicaid expenditures, including reductions in pharmaceutical spending, hospitalizations, assisted living, and hospice costs, while also clarifying the administrative resources needed for safe implementation. Understanding both savings and system requirements provides Congress with the evidence base necessary to evaluate future coverage models and broader reforms.
Purpose: Congress needs reliable information on potential Medicare and Medicaid savings, coverage models, and administrative costs before evaluating broader healthcare integration or coverage reforms.
PROPOSED COMMITTEE REPORT LANGUAGE:
Medical Cannabis and Federal Healthcare Program Research. The Committee directs CMS to conduct or support research on the impact of state-authorized medical cannabis use on Medicare and Medicaid beneficiaries, including healthcare costs, prescription drug utilization, opioid use, hospitalizations, long-term care utilization, hospice care, pain management, patient-reported outcomes, adverse events, and care coordination. The Committee further directs CMS to evaluate whether standardized documentation of therapeutic medical cannabis use would improve patient safety, care coordination, drug-interaction screening, and federal healthcare program integrity.
| D. ESTABLISH AN HHS OFFICE OF MEDICAL CANNABIS & CANNABINOID CONTROL |
Establishing a centralized Office of Medical Cannabis and Cannabinoid Control within HHS ensures that the Department can hire experts to address cannabis and cannabinoid policy issues and to prevent duplicative spending across agencies. Centralizing responsibility also provides Congress with a clear structure for future policymaking, reducing uncertainty and enabling long-term regulatory planning.
Purpose: Rescheduling alone will not create patient protections, healthcare integration, research advancement, product safety standards, or consistent federal implementation. HHS needs an operational office to coordinate medical cannabis policy across CMS, FDA, NIH, DOJ, HUD, VA, DOD, OPM, SAMHSA, Treasury, IRS, FinCEN, state regulators, Tribal governments, patients, clinicians, and researchers.
PROPOSED BILL LANGUAGE:
SEC. __. OFFICE OF MEDICAL CANNABIS CANNABINOID CONTROL. The Secretary of Health and Human Services shall use funds made available under this Act, including funds available within the Department’s discretionary budget, to establish an Office of Medical Cannabis and Cannabinoid Control (OMC) within the Department of Health and Human Services.
The Office shall support implementation across research, healthcare delivery, civil rights, product safety, clinical documentation, patient access, state-federal coordination, hemp-derived cannabinoid regulation, and federal program alignment, including the implementation of AG Order No. 6754-2026, the Medical Marijuana and Cannabidiol Research Expansion Act, and Executive Order 14370.
The Office shall be responsible for coordinating and overseeing the implementation of the directives contained in Sections __ and __ of this Act regarding standardized medical cannabis data collection, CMS studies on cost savings and coverage models, and the integration of such data into Medicare and Medicaid programs.
The Office shall also oversee the responsibilities of the Secretary and the Food and Drug Administration under section 781 of H.R. 5371 relating to cannabis and cannabinoid regulation; coordinate with the Centers for Medicare & Medicaid Services regarding requirements under 42 CFR 422.102(f)(1)(iii)(G); and ensure that cannabis- and cannabinoid-related research funded by the National Institutes of Health is conducted in accordance with applicable federal standards,
The Secretary shall ensure that the Office is staffed with individuals possessing clinical, regulatory, scientific, and public health expertise relevant to medical cannabis and cannabinoid therapeutics.
|
E. HHS & SAMHSA: FEDERAL WORKPLACE TESTING STANDARDS |
Direct HHS and SAMHSA to participate with OPM and DOJ in updating federal workplace medical cannabis guidance, distinguishing medical use and cannabis exposure from evidence of current impairment. The agencies should jointly evaluate pre-employment and random cannabis testing, medical-review procedures, clinical documentation, protections for sensitive medical information, and the use of test results in employment decisions.
Purpose: HHS and SAMHSA oversee the scientific and technical guidelines used in federal workplace drug-testing programs. An appropriations-directed review can examine whether testing protocols and workplace practices are aligned with current federal medical cannabis policy, appropriate disability-law standards, individualized assessment, and genuine safety requirements.
SAMPLE COMMITTEE REPORT LANGUAGE
Federal Workplace Cannabis Testing and Clinical Review. The Committee directs the Department of Health and Human Services, acting through the Substance Abuse and Mental Health Services Administration, to work with OPM and DOJ to assess pre-employment and random cannabis-testing practices, medical review officer procedures, and federal guidance for state-authorized medical cannabis patients in federal employment and contracting. HHS shall provide technical recommendations on the distinction between cannabis detection and contemporaneous impairment, confidentiality, clinical documentation, disability-related individualized assessment, and safety-sensitive duties, and submit those recommendations to the Committees on Appropriations within 180 days.
|
F. CLINICAL IMPLEMENTATION AND CORRECTION OF INACCURATE RECORDS |
Direct HHS and CMS to issue system-wide implementation guidance for federally funded healthcare settings, including hospitals, hospices, nursing homes, assisted living facilities, federally qualified health centers, transplant programs, pain clinics, and Medicare- and Medicaid-participating providers. The guidance should cover individualized requests, clinician-patient discussions, therapeutic documentation, care coordination, drug-interaction review, clinically appropriate accommodation, and consultation with DEA where dispensing or on-site administration raises registration questions.
Direct participating healthcare entities to provide a process for reviewing and, where medically appropriate, correcting existing medical records in which state-authorized medical cannabis treatment was inaccurately characterized as illicit drug use, non-medical use, or substance-use-disorder history.
PROPOSED COMMITTEE REPORT LANGUAGE:
The Committee directs HHS and CMS to issue practical implementation instructions for clinical documentation, care coordination, patient safety, reasonable-accommodation reviews, and correcting prior records related to state-authorized medical cannabis treatment. The agencies shall identify any registration, funding, certification, or reimbursement questions requiring further guidance and provide model training materials to participating providers.
|
G. HHS INTERAGENCY IMPLEMENTATION PLAN & PATIENT CONSULTATION |
The proposed HHS Office of Medical Cannabis and Cannabinoid Control should prepare an initial interagency implementation plan addressing patient protections, medical record standards, research, care integration, product safety, hemp-derived cannabinoids, state-federal coordination, and implementation of DEA registration. Consultation should include patients, caregivers, clinicians, state medical cannabis regulators, disability-rights advocates, veterans, researchers, and Tribal governments.
PROPOSED COMMITTEE REPORT LANGUAGE:
The Committee directs HHS, through its Office of Medical Cannabis and Cannabinoid Control, if established, to provide an initial federal implementation plan within 90 days of establishment and to establish a process for ongoing consultation with patients, caregivers, clinical experts, state regulators, and Tribal governments.
DOWNLOAD PROPOSED HHS APPROPS LANGUAGE| TAKE ACTION
THE PATH FORWARD |
The priorities outlined here are part of Americans for Safe Access' coordinated FY2027 appropriations agenda across seven congressional subcommittees. Together, these requests seek to protect patients, remove discriminatory barriers, strengthen federal accountability, and establish the policies necessary to integrate medical cannabis into American healthcare.
Congress can take meaningful action through the appropriations process while laying the groundwork for comprehensive medical cannabis legislation in the 120th Congress. Patients should not have to choose between the medicine they rely on and their healthcare, housing, livelihoods, or fundamental rights. Explore ASA's complete FY2027 Medical Cannabis Appropriations Agenda to learn how these requests work together and follow the latest congressional developments.
The Path Forward: The Medical Cannabis & Cannabinoid Act
References & Sources
|
Share this page